The effect of an oral nutritional supplement enriched with fish oil on weight loss in patients with pancreatic cancer

被引:299
作者
Barber, MD
Ross, JA
Voss, AC
Tisdale, MJ
Fearon, KCH [1 ]
机构
[1] Univ Edinburgh, Royal Infirm Edinburgh, Dept Surg, Edinburgh EH8 9JA, Midlothian, Scotland
[2] Abbott Labs, Ross Prod Div, Columbus, OH 43215 USA
[3] Aston Univ, Dept Pharmaceut Sci, Birmingham B4 7ET, W Midlands, England
关键词
pancreatic cancer; cachexia; eicosapentaenoic acid; docosahexaenoic acid; fish oil; nutritional supplementation;
D O I
10.1038/sj.bjc.6690654
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies have suggested that administration of oral eicosapentaenoic acid (EPA) will stabilize weight in patients with advanced pancreatic cancer. The aim of the present study was to determine ii a combination of EPA with a conventional oral nutritional supplement could produce weight gain in these patients. Twenty patients with unresectable pancreatic adenocarcinoma were asked to consume two cans of a fish oil-enriched nutritional supplement per day in addition to their normal food intake, Each can contained 310 kcal, 16.1 g protein and 1.09 g EPA. Patients were assessed for weight, body composition, dietary intake, resting energy expenditure (REE) and performance status. Patients consumed a median of 1.9 cans day(-1), All patients were losing weight at baseline at a median rate of 2.9 kg month(-1). After administration of the fish oil-enriched supplement, patients had significant weight-gain at both 3 (median 1 kg, P = 0.024) and 7 weeks (median 2 kg, P = 0.033), Dietary intake increased significantly by almost 400 kcal day(-1) (P = 0.002), REE per kg body weight and per kg lean body mass fell significantly. Performance status and appetite were significantly improved at 3 weeks. In contrast to previous studies of oral conventional nutritional supplements in weight-losing cancer patients, this study suggests that an EPA-enriched supplement may reverse cachexia in advanced pancreatic cancer.
引用
收藏
页码:80 / 86
页数:7
相关论文
共 39 条
[1]  
Ahlgren JD, 1996, SEMIN ONCOL, V23, P241
[2]  
BARBER MD, 1997, PROSTAGLANDINS LEUKO, V57, P204
[3]  
BECK SA, 1991, CANCER RES, V51, P6089
[4]  
Cohn S H, 1982, Nutr Cancer, V4, P107, DOI 10.1080/01635588209513746
[5]   PROGNOSTIC EFFECT OF WEIGHT-LOSS PRIOR TO CHEMOTHERAPY IN CANCER-PATIENTS [J].
DEWYS, WD ;
BEGG, C ;
LAVIN, PT ;
BAND, PR ;
BENNETT, JM ;
BERTINO, JR ;
COHEN, MH ;
DOUGLASS, HO ;
ENGSTROM, PF ;
EZDINLI, EZ ;
HORTON, J ;
JOHNSON, GJ ;
MOERTEL, CG ;
OKEN, MM ;
PERLIA, C ;
ROSENBAUM, C ;
SILVERSTEIN, MN ;
SKEEL, RT .
AMERICAN JOURNAL OF MEDICINE, 1980, 69 (04) :491-497
[6]   A RANDOMIZED STUDY OF ORAL NUTRITIONAL SUPPORT VERSUS AD-LIB NUTRITIONAL INTAKE DURING CHEMOTHERAPY FOR ADVANCED COLORECTAL AND NON-SMALL-CELL LUNG-CANCER [J].
EVANS, WK ;
NIXON, DW ;
DALY, JM ;
ELLENBERG, SS ;
GARDNER, L ;
WOLFE, E ;
SHEPHERD, FA ;
FELD, R ;
GRALLA, R ;
FINE, S ;
KEMENY, N ;
JEEJEEBHOY, KN ;
HEYMSFIELD, S ;
HOFFMAN, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :113-124
[7]  
FALCONER JS, 1995, CANCER, V75, P2077, DOI 10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO
[8]  
2-9
[9]   CYTOKINES, THE ACUTE-PHASE RESPONSE, AND RESTING ENERGY-EXPENDITURE IN CACHECTIC PATIENTS WITH PANCREATIC-CANCER [J].
FALCONER, JS ;
FEARON, KCH ;
PLESTER, CE ;
ROSS, JA ;
CARTER, DC .
ANNALS OF SURGERY, 1994, 219 (04) :325-331
[10]   EFFECT OF EICOSAPENTAENOIC ACID AND OTHER FATTY-ACIDS ON THE GROWTH IN-VITRO OF HUMAN PANCREATIC-CANCER CELL-LINES [J].
FALCONER, JS ;
ROSS, JA ;
FEARON, KCH ;
HAWKINS, RA ;
ORIORDAIN, MG ;
CARTER, DC .
BRITISH JOURNAL OF CANCER, 1994, 69 (05) :826-832